Novel Interactions between Mas and Angiotensin Receptors and Their Functionality Modulatory Role for the Brain RAS

Abstract

The renin–angiotensin system (RAS) not only plays an important role in controlling blood pressure, but also participates in almost every process to maintain homeostasis in mammals. The occurrence of RAS in the basal ganglia suggests that the system may be targeted to improve the therapy of neurodegenerative diseases. We found heteromers formed by Mas and angiotensin receptors, and addressed their functionality in neurons and microglia. Novel interactions formed by MAS/AT1R and MAS/AT2R were discovered by using resonance energy transfer techniques. In the heterologous system, we showed that the three receptors—MasR, AT1R, and AT2R—can interact to form heterotrimers (Figure S1). The functionality of individual and interacting receptors was assayed by measuring levels of the second messengers cAMP and Ca2+ in transfected human embryonic kidney cells (HEK-293T) (Figure S2) and primary cultures of striatal cells. Expression (Figure S3) and functionality (Figure S4) were assayed in parallel in primary cultures of microglia treated or not treated with lipopolysaccharide and interferon-γ (IFN-γ) to simulate neuroinflammation conditions. The proximity ligation assay (PLA) was used to assess heteromer expression in parkinsonian and dyskinetic conditions (Figure S4). In all cases, agonist-induced signaling was reduced upon coactivation, and in some cases just by coexpression. In addition, the blockade of signaling of two receptors in a complex by the action of a given (selective) receptor antagonist (cross-antagonism) was often observed. The negative modulation of calcium mobilization (mediated by AT1R activation), the multiplicity of possibilities on RAS affecting the MAPK pathway, and the disbalanced expression of heteromers in dyskinesia yield new insights into the operation of the RAS system, how it becomes unbalanced, and how a disbalanced RAS system can be rebalanced. Furthermore, RAS components in activated microglia warrant attention in drug development approaches to address neurodegeneration.